Is SCHD a Good ETF to Buy?
With around $65.7 billion in net assets, Schwab’s US Dividend…
Sell
48
MOLN Quote, Financials, Valuation and Earnings
Last price:
$5.43
Seasonality move
:
-0.31%
Day range:
$5.26 - $5.46
52-week range:
$3.32 - $12.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
26.52x
P/B ratio:
1.22x
Volume:
4K
Avg. volume:
18.4K
1-year change:
28.5%
Market cap:
$201.1M
Revenue:
$7.8M
EPS (TTM):
-$2.14
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MOLN
Molecular Partners AG
|
-- | -$0.45 | -100% | -33.3% | $10.51 |
|
ACIU
AC Immune SA
|
$633.2K | -$0.22 | -96.21% | -284.28% | $10.25 |
|
ADXN
Addex Therapeutics
|
$177.2K | -- | 2.35% | -- | $30.00 |
|
CRSP
CRISPR Therapeutics AG
|
$7.4M | -$1.21 | -96.15% | -0.36% | $84.08 |
|
MLTX
MoonLake Immunotherapeutics
|
-- | -$0.62 | -- | -551.43% | -- |
|
NLSP
NLS Pharmaceutics
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MOLN
Molecular Partners AG
|
$5.46 | $10.51 | $201.1M | -- | $0.00 | 0% | 26.52x |
|
ACIU
AC Immune SA
|
$2.93 | $10.25 | $289.9M | -- | $0.00 | 0% | -- |
|
ADXN
Addex Therapeutics
|
$8.20 | $30.00 | $8.8M | -- | $0.00 | 0% | 15.15x |
|
CRSP
CRISPR Therapeutics AG
|
$41.92 | $84.08 | $3.6B | -- | $0.00 | 0% | -- |
|
MLTX
MoonLake Immunotherapeutics
|
$50.21 | -- | $3.2B | -- | $0.00 | 0% | -- |
|
NLSP
NLS Pharmaceutics
|
$2.06 | -- | $7.9M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MOLN
Molecular Partners AG
|
-- | 2.282 | -- | 14.08x |
|
ACIU
AC Immune SA
|
-- | 5.710 | -- | 1.82x |
|
ADXN
Addex Therapeutics
|
-- | 3.160 | -- | 4.36x |
|
CRSP
CRISPR Therapeutics AG
|
-- | 3.448 | -- | -- |
|
MLTX
MoonLake Immunotherapeutics
|
-- | 1.800 | -- | -- |
|
NLSP
NLS Pharmaceutics
|
-- | 2.905 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MOLN
Molecular Partners AG
|
-- | -$16.9M | -37.36% | -37.36% | -2407.93% | -$17.3M |
|
ACIU
AC Immune SA
|
-- | $8.4M | -28.55% | -28.55% | 21.72% | -$12.8M |
|
ADXN
Addex Therapeutics
|
-- | -$719.5K | 91.08% | 91.08% | -2836.3% | -$713.3K |
|
CRSP
CRISPR Therapeutics AG
|
-$11.2M | -$110.1M | -- | -- | -- | -$107.1M |
|
MLTX
MoonLake Immunotherapeutics
|
-- | -$43.1M | -- | -- | -- | -$25.4M |
|
NLSP
NLS Pharmaceutics
|
-- | -- | -- | -- | -- | -- |
Molecular Partners AG vs. Competitors
-
Which has Higher Returns MOLN or ACIU?
AC Immune SA has a net margin of -2408.81% compared to Molecular Partners AG's net margin of 21.59%. Molecular Partners AG's return on equity of -37.36% beat AC Immune SA's return on equity of -28.55%.
Company Gross Margin Earnings Per Share Invested Capital MOLNMolecular Partners AG-- -$0.57 $165M ACIUAC Immune SA-- $0.06 $154.7M -
What do Analysts Say About MOLN or ACIU?
Molecular Partners AG has a consensus price target of $10.51, signalling upside risk potential of 92.56%. On the other hand AC Immune SA has an analysts' consensus of $10.25 which suggests that it could grow by 249.67%. Given that AC Immune SA has higher upside potential than Molecular Partners AG, analysts believe AC Immune SA is more attractive than Molecular Partners AG.
Company Buy Ratings Hold Ratings Sell Ratings MOLNMolecular Partners AG2 1 0 ACIUAC Immune SA3 0 0 -
Is MOLN or ACIU More Risky?
Molecular Partners AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.294, suggesting its more volatile than the S&P 500 by 29.428%.
-
Which is a Better Dividend Stock MOLN or ACIU?
Molecular Partners AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Molecular Partners AG pays -- of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MOLN or ACIU?
Molecular Partners AG quarterly revenues are $787.5K, which are smaller than AC Immune SA quarterly revenues of $29.5M. Molecular Partners AG's net income of -$19M is lower than AC Immune SA's net income of $6.4M. Notably, Molecular Partners AG's price-to-earnings ratio is -- while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Molecular Partners AG is 26.52x versus -- for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MOLNMolecular Partners AG26.52x -- $787.5K -$19M ACIUAC Immune SA-- -- $29.5M $6.4M
-
Which has Higher Returns MOLN or ADXN?
Addex Therapeutics has a net margin of -2408.81% compared to Molecular Partners AG's net margin of -2841.85%. Molecular Partners AG's return on equity of -37.36% beat Addex Therapeutics's return on equity of 91.08%.
Company Gross Margin Earnings Per Share Invested Capital MOLNMolecular Partners AG-- -$0.57 $165M ADXNAddex Therapeutics-- -$2.78 $13.1M -
What do Analysts Say About MOLN or ADXN?
Molecular Partners AG has a consensus price target of $10.51, signalling upside risk potential of 92.56%. On the other hand Addex Therapeutics has an analysts' consensus of $30.00 which suggests that it could grow by 265.85%. Given that Addex Therapeutics has higher upside potential than Molecular Partners AG, analysts believe Addex Therapeutics is more attractive than Molecular Partners AG.
Company Buy Ratings Hold Ratings Sell Ratings MOLNMolecular Partners AG2 1 0 ADXNAddex Therapeutics0 0 0 -
Is MOLN or ADXN More Risky?
Molecular Partners AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Addex Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MOLN or ADXN?
Molecular Partners AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Molecular Partners AG pays -- of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MOLN or ADXN?
Molecular Partners AG quarterly revenues are $787.5K, which are larger than Addex Therapeutics quarterly revenues of $62.3K. Molecular Partners AG's net income of -$19M is lower than Addex Therapeutics's net income of -$1.8M. Notably, Molecular Partners AG's price-to-earnings ratio is -- while Addex Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Molecular Partners AG is 26.52x versus 15.15x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MOLNMolecular Partners AG26.52x -- $787.5K -$19M ADXNAddex Therapeutics15.15x -- $62.3K -$1.8M
-
Which has Higher Returns MOLN or CRSP?
CRISPR Therapeutics AG has a net margin of -2408.81% compared to Molecular Partners AG's net margin of --. Molecular Partners AG's return on equity of -37.36% beat CRISPR Therapeutics AG's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MOLNMolecular Partners AG-- -$0.57 $165M CRSPCRISPR Therapeutics AG-- -$1.01 -- -
What do Analysts Say About MOLN or CRSP?
Molecular Partners AG has a consensus price target of $10.51, signalling upside risk potential of 92.56%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $84.08 which suggests that it could grow by 100.58%. Given that CRISPR Therapeutics AG has higher upside potential than Molecular Partners AG, analysts believe CRISPR Therapeutics AG is more attractive than Molecular Partners AG.
Company Buy Ratings Hold Ratings Sell Ratings MOLNMolecular Partners AG2 1 0 CRSPCRISPR Therapeutics AG11 11 2 -
Is MOLN or CRSP More Risky?
Molecular Partners AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.681, suggesting its more volatile than the S&P 500 by 68.115%.
-
Which is a Better Dividend Stock MOLN or CRSP?
Molecular Partners AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Molecular Partners AG pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MOLN or CRSP?
Molecular Partners AG quarterly revenues are $787.5K, which are larger than CRISPR Therapeutics AG quarterly revenues of --. Molecular Partners AG's net income of -$19M is higher than CRISPR Therapeutics AG's net income of -$85.9M. Notably, Molecular Partners AG's price-to-earnings ratio is -- while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Molecular Partners AG is 26.52x versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MOLNMolecular Partners AG26.52x -- $787.5K -$19M CRSPCRISPR Therapeutics AG-- -- -- -$85.9M
-
Which has Higher Returns MOLN or MLTX?
MoonLake Immunotherapeutics has a net margin of -2408.81% compared to Molecular Partners AG's net margin of --. Molecular Partners AG's return on equity of -37.36% beat MoonLake Immunotherapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MOLNMolecular Partners AG-- -$0.57 $165M MLTXMoonLake Immunotherapeutics-- -$0.56 -- -
What do Analysts Say About MOLN or MLTX?
Molecular Partners AG has a consensus price target of $10.51, signalling upside risk potential of 92.56%. On the other hand MoonLake Immunotherapeutics has an analysts' consensus of -- which suggests that it could grow by 47.23%. Given that Molecular Partners AG has higher upside potential than MoonLake Immunotherapeutics, analysts believe Molecular Partners AG is more attractive than MoonLake Immunotherapeutics.
Company Buy Ratings Hold Ratings Sell Ratings MOLNMolecular Partners AG2 1 0 MLTXMoonLake Immunotherapeutics11 3 0 -
Is MOLN or MLTX More Risky?
Molecular Partners AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison MoonLake Immunotherapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MOLN or MLTX?
Molecular Partners AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MoonLake Immunotherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Molecular Partners AG pays -- of its earnings as a dividend. MoonLake Immunotherapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MOLN or MLTX?
Molecular Partners AG quarterly revenues are $787.5K, which are larger than MoonLake Immunotherapeutics quarterly revenues of --. Molecular Partners AG's net income of -$19M is higher than MoonLake Immunotherapeutics's net income of -$35.4M. Notably, Molecular Partners AG's price-to-earnings ratio is -- while MoonLake Immunotherapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Molecular Partners AG is 26.52x versus -- for MoonLake Immunotherapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MOLNMolecular Partners AG26.52x -- $787.5K -$19M MLTXMoonLake Immunotherapeutics-- -- -- -$35.4M
-
Which has Higher Returns MOLN or NLSP?
NLS Pharmaceutics has a net margin of -2408.81% compared to Molecular Partners AG's net margin of --. Molecular Partners AG's return on equity of -37.36% beat NLS Pharmaceutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MOLNMolecular Partners AG-- -$0.57 $165M NLSPNLS Pharmaceutics-- -- -- -
What do Analysts Say About MOLN or NLSP?
Molecular Partners AG has a consensus price target of $10.51, signalling upside risk potential of 92.56%. On the other hand NLS Pharmaceutics has an analysts' consensus of -- which suggests that it could grow by 11550.49%. Given that NLS Pharmaceutics has higher upside potential than Molecular Partners AG, analysts believe NLS Pharmaceutics is more attractive than Molecular Partners AG.
Company Buy Ratings Hold Ratings Sell Ratings MOLNMolecular Partners AG2 1 0 NLSPNLS Pharmaceutics0 0 0 -
Is MOLN or NLSP More Risky?
Molecular Partners AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NLS Pharmaceutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MOLN or NLSP?
Molecular Partners AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NLS Pharmaceutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Molecular Partners AG pays -- of its earnings as a dividend. NLS Pharmaceutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MOLN or NLSP?
Molecular Partners AG quarterly revenues are $787.5K, which are larger than NLS Pharmaceutics quarterly revenues of --. Molecular Partners AG's net income of -$19M is higher than NLS Pharmaceutics's net income of --. Notably, Molecular Partners AG's price-to-earnings ratio is -- while NLS Pharmaceutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Molecular Partners AG is 26.52x versus -- for NLS Pharmaceutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MOLNMolecular Partners AG26.52x -- $787.5K -$19M NLSPNLS Pharmaceutics-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is NAIL a Good ETF to Buy?
If you’re thinking about buying the NAIL ETF, this article…
3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Stock Ideas
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Sell
43
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
57
NARI alert for Jan 8
Inari Medical [NARI] is down 0.18% over the past day.
Buy
69
UNF alert for Jan 8
UniFirst [UNF] is up 2.79% over the past day.
Sell
31
APOG alert for Jan 8
Apogee Enterprises [APOG] is down 9.15% over the past day.
